BioLineRx Ltd (NASDAQ:BLRX) Q1 2020 Earnings Conference Call - Final Transcript
May 20, 2020 • 10:00 am ET
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx's First Quarter 2020 Results Conference Call. [Operator Instructions].
I would now like to turn the call to Timothy McCarthy of LifeSci Advisors to read the Safe Harbor statement. Tim, please go ahead.
Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call other than historical facts are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements.
These forward-looking statements are not guarantees the future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include, but are not limited to the risk factors and other qualifications contained in BioLineRx's Annual Report on Form 20-F, quarterly reports filed in the 6-K and other reports filed by BioLineRx with the SEC to which your attention is directed.
Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or [Technical Issues].
At this time, it's now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.
Philip A. Serlin
Thank you, Tim, and good morning, everyone. And thank you for joining us on our first quarter earnings conference call today. Earlier this morning, we issued our Q1 results press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6-K.
I will begin with some brief prepared remarks and then, Mali Zeevi, our Chief Financial Officer will provide a short discussion of our financial results. We will then open up the call to your questions. Also joining the call for Q&A, are Abi Vainstein, our Vice President, Clinical Development; and Ella Sorani, our Vice President, Research and Development.
Before turning to the results, I would like to make a comment about the humanitarian and economic crisis brought on by COVID-19. We, like many companies have quickly adapted to a remote working environment that puts our employees in the best position to remain safe while continuing to work toward our collective goals as a company.
The pandemic has caused unprecedented disruptions in day-to-day activities and has resulted in delays to drug development timelines around the world, given the difficulty of advancing ongoing trials and recruiting patients for new trials.
Recall that our lead clinical candidate, Motixafortide, formerly BL-8040, is currently being evaluated in several studies across multiple cancer indications, including advanced metastatic pancreatic cancer, stem cell mobilization in AML. We also have a second clinical candidate the anti-cancer vaccine AGI-134, that is being evaluated in solid tumors.
We believe that having multiple clinical trials at various stages of completion will help us navigate through this crisis even while some of our programs may experience COVID-related delays.